Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
November 16 2023 - 4:05PM
Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing
and precision medicine, and Personalis, Inc., a leader in advanced
genomics for precision oncology, (Nasdaq: PSNL) today announced a
non-exclusive collaboration through which Myriad will market the
Personalis® ImmunoID NeXT ultra-comprehensive biomarker discovery
platform to its pharmaceutical partners who use the MyRisk®
Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx
cancer tests.
“An increasing number of our companion diagnostic pharmaceutical
partners are requesting complementary whole exome and whole
transcriptome testing on their patients’ tumors,” said Paul Diaz,
President and CEO, Myriad Genetics. “Our goal is to provide full
menu access to our customers and we are pleased to leverage
Personalis’ high quality assays to expand our offering.”
Personalis’ ImmunoID NeXT platform is the most discriminating
platform to power drug development biomarker efforts and has been
utilized by the top 20 global bio-pharma companies. It provides
high-quality exome/transcriptome assays for cancer FFPE
samples.
“A key pillar of our strategy is to expand our reach through
commercial partnerships and this new collaboration with Myriad is
an exciting milestone of our progress,” said Chris Hall, CEO and
President of Personalis.
Financial details of the partnership were not disclosed.
About Myriad Genetics, Inc.
Myriad Genetics is a leading genetic testing and precision
medicine company dedicated to advancing health and well-being for
all. Myriad develops and offers genetic tests that help assess the
risk of developing disease or disease progression and guide
treatment decisions across medical specialties where genetic
insights can significantly improve patient care and lower
healthcare costs. For more information, visit www.myriad.com.
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest timepoints, enable selection of targeted
therapies based on ultra-comprehensive genomic profiling, and
enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X
(Twitter).
Personalis Forward-Looking StatementsThis press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
the ImmunoID NeXT Platform. Such forward-looking statements involve
known and unknown risks and uncertainties and other factors that
may cause actual results to differ materially from any anticipated
results or expectations expressed or implied by such statements,
including the risks, uncertainties and other factors that relate to
Personalis’ ability to demonstrate attributes or advantages of the
Personalis NeXT Platform. These and other potential risks and
uncertainties that could cause actual results to differ materially
from the results predicted in these forward-looking statements are
described under the captions “Risk Factors”and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in Personalis’ Annual Report on Form 10-K for the year
ended December 31, 2022, filed with the Securities and Exchange
Commission (SEC) on February 23, 2023, and its Quarterly Report on
Form 10-Q for the quarter ended September 30, 2023, filed with the
SEC on November 7, 2023. All information provided in this release
is as of the date of this press release, and any forward-looking
statements contained herein are based on assumptions that we
believe to be reasonable as of this date. Undue reliance should not
be placed on the forward-looking statements in this press release,
which are based on information available to us on the date hereof.
Personalis undertakes no duty to update this information unless
required by law.
Myriad Forward-Looking StatementsThis press
release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
that Myriad will market the Personalis ImmunoID NeXT
ultra-comprehensive biomarker discovery platform to its
pharmaceutical partners who use the MyRisk Hereditary Cancer Test,
BRACAnalysis CDx and/or MyChoice CDx cancer tests. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Personalis Investor Contact:Caroline
Cornerinvestors@personalis.com415-202-5678
Personalis Media Contact:pr@personalis.com
Myriad Genetics Media Contact:Glenn
Farrell(385) 318-3718PR@myriad.com
Myriad Genetics Investor Contact:Matt
Scalo(801) 584-3532IR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024